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Abstract
Aquaporin (AQP) is a family of transmembrane proteins for water transport. Recent studies revealed that AQPs are likely to
play a role in tumor progression and invasion. We aimed to examine the potential role of AQP5 in the progression of human
breast cancer cells. Expression of AQP5 mRNA and protein was seen in human breast cancer cell line (both MCF7 and MDA-
MB-231) by RT-PCR and immunoblotting analysis. Immunoperoxidase labeling of AQP5 was observed at ductal epithelial
cells of human breast tissues. In benign tumor, AQP5 labeling was mainly seen at the apical domains of ductal epithelial
cells. In contrast, in invasive ductal carcinoma, prominent AQP5 labeling was associated with cancer cells, whereas some
ducts were unlabeled and apical polarity of AQP5 in ducts was lost. Cell proliferation (BrdU incorporation assay) and
migration of MCF7 cells were significantly attenuated by lentivirus-mediated AQP5-shRNA transduction. Hyperosmotic
stress induced by sorbitol treatment (100 mM, 24 h) reduced AQP5 expression in MCF7 cells, which was also associated with
a significant reduction in cell proliferation and migration. Taken together, prominent AQP5 expression in breast cancer cells
with the loss of polarity of ductal epithelial cells was seen during the progression of breast carcinoma. shRNA- or
hyperosmotic stress-induced reduction in AQP5 expression of MCF7 cells was associated with significantly reduced cell
proliferation and migration. In conclusion, AQP5 overexpression is likely to play a role in cell growth and metastasis of
human breast cancer and could be a novel target for anti-breast cancer treatment.
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Introduction
Water channel protein aquaporin (aquaporin: AQP) is a family
of transmembrane proteins for water transport, and expression of
13 subtypes has been reported in mammals [1]. AQPs regulate
cellular water transport and cell volume and play a key role in
body water homeostasis. Some subtypes of AQPs (called as
aquaglyceroporins) are also involved in the transport of other
molecules such as glycerol and urea [2]. In addition, AQPs
mediate signals as membrane proteins by transporting signaling
molecules or coupling with other proteins [3,4]. Importantly,
recent studies revealed that AQPs are recognized as the targets for
novel anti-tumor therapy, since they are likely to play a role in the
promotion of tumor progression and invasion [5,6,7].
Altered expression of AQPs has been revealed in several types of
tumors upon their specific tissue localization. AQP1, AQP4, and
AQP9 are mainly expressed in brain tumor [8,9], and among
them AQP4 is particularly important due to its up-regulation in
malignant tumor and brain edema [10]. In the studies of AQP3-
null mice, AQP3 gene deletion induces the resistance to
carcinogen-induced skin tumor [6]. Glycerol transport through
AQP3 also contributes to the generation of ATP for cell
proliferation and tumorigenesis [6]. Moreover, AQP1 is widely
over-expressed in tumor tissues of brain, lung, prostate, and colon
[7,11,12,13], and AQP3 and AQP5 are also expressed in the
colorectal carcinoma [7].
In particular, AQP5 expression in colon cancer cell lines and
human colon cancer tissues is associated with cell proliferation and
metastasis to liver [14], suggesting that altered expression of AQP5
could play a role in tumor progression [14,15,16,17,18].
Consistent with this, Ras signal transduction was suggested for
enhanced cell proliferation in AQP5-overexpressed in NIH3T3
cells [4]. Moreover, a study for the molecular interaction between
AQP5 and its downstream pathway leading to cell invasion
revealed that AQP5 binds to SH3 domains of c-Src, a non-
receptor cytoplasmic tyrosine kinase associated with invasive and
metastatic phenotype in various tumors [15].
Shillingford, et al. demonstrated the immunolocalization of
AQP5 in the ductal epithelial cells of mouse mammary gland [19].
Since AQP5 is highly expressed in the mammary tumor library,
AQP5 may be an important marker protein involved in
tumorigenesis and progression. However, the role of AQP5
expression in human breast tissue has not been studied. In this
study, we aimed to examine the potential role of AQP5 in the
progression of human breast cancer cells by studying 1) the
expression of AQP5 in human breast cancer cells (MCF7 and
MDA-MB-231 cell lines) and the immunolocalization of AQP5 in
human breast cancer tissues; 2) the changes of cellular and
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and invasive ductal carcinoma with or without lymph node (LN)
metastasis in human patients; 3) the changes of AQP5 expression
related to breast cancer grade; 4) the effects of AQP5 knockdown
by lentivirus-mediated shRNA transduction on the cell prolifer-
ation and migration of human breast cancer cells (MCF7 cells);
and 5) the effects of altered tumor microenvironment (i.e.,
extracellular hyperosmolality induced by sorbitol treatment) on
the AQP5 expression, cell proliferation and migration of human
breast cancer cells (MCF7 cells).
Results
AQP5 expression in human breast cancer cells
Expression of AQP5 mRNA and protein was investigated in
human breast cancer cell lines (both MCF7 and MDA-MB-231
cells) by reverse transcriptase-PCR (RT-PCR) and immunoblot-
ting analysis. RT-PCR analysis revealed the AQP5 products
(189 bp) in both MCF7 and MDAMB-231 cells (Fig. 1A). The
reaction without RT was used as a negative control and human
lung cancer cell line A549, the AQP5-expressing cancer cell line
[20], was used as a positive control for AQP5 expression (Fig. 1A).
Immunoblotting analysis also revealed that both human breast
cancer cell lines express AQP5 protein (Fig. 1B).
Immunohistochemistry of AQP5 in human breast cancer
In the tissue sections of benign breast tumor, immunoperoxidase
labeling of AQP5 was exclusively associated with ductal epithelial
cells (Fig. 2A–C). AQP5 labeling in the ductal epithelial cells was
mainly in the apical plasma membrane domain (arrowheads in
Fig. 2B, C). In contrast, in the tissue sections of invasive ductal
carcinoma of breast (Fig. 2D–I), AQP5 labeling was also associated
with invasive tumor cells (arrows in Fig. 2D, G–I), in addition to
the ductal epithelial cells. More prominent AQP5 labeling was
associated with invasive cancer cells, particularly in the invasive
ductal carcinoma with lymph node (LN) metastasis (arrows in
Fig. 2G–I), whereas the labeling was weaker in the invasive ductal
carcinoma without lymph node metastasis (arrows in Fig. 2D). The
apical polarity of AQP5 labeling in ductal epithelial cells was
rarely seen (Fig. 2F, H) and the labeling pattern became diffuse
intracellularly (Fig. 2H). Moreover, in the breast cancer tissues
with LN metastasis some ducts were unlabeled (Fig. 2I). Thus, the
results demonstrated an intense AQP5 labeling in the invasive
cancer cells combined with the gradual decrease of AQP5 labeling
in the ductal cells, along with the loss of AQP5 polarity in the
apical plasma membrane domain during the progression of breast
carcinoma.
Importantly, semi-quantitative measurement of AQP5 labeling
intensity demonstrated that AQP5 labeling intensity was more
prominent in the invasive tumor cells when LNs were involved
(Table 1). Moreover, the approximate numbers of AQP5-positive
tumor cells among the total tumor cells were increased (Table 1).
In contrast, the tumor grade based on the modified Bloom-
Richardson-Elston grading system was not different between LN
(+) invasive carcinoma and LN (-) invasive carcinoma (Table 1).
Inhibition of cell proliferation and migration of MCF7
cells in response to shRNA-mediated knockdown of
AQP5
To examine whether AQP5 expression plays a role in the
progression of breast cancer in human patients, changes of
proliferation and migration of breast cancer cells were examined
in response to shRNA-mediated knockdown of AQP5. AQP5
protein expression in MCF7 cells was significantly decreased by
lentivirus-mediated AQP5 shRNA transduction (6467% of
control level, P,0.05, Fig. 3A and B), whereas ERa expression
was unchanged. BrdU cell proliferation assay demonstrated that
BrdU incorporation was significantly decreased (6962% of mock
control, P,0.05, Fig. 3C) in MCF7 cells with AQP5 knockdown,
indicating that AQP5 knockdown in human breast cancer cells
was associated with decreased cell proliferation. Moreover,
migrating ability of MCF7 cells was examined by FBS gradient-
induced cell migration assay. The number of migrated MCF7 cells
was significantly decreased (4764% of mock control, P,0.05,
Fig. 3D, E) in response to AQP5 knockdown.
Inhibition of AQP5 expression in MCF7 cells in response
to sorbitol treatment
Hyperosmotic stress is known to change AQPs expression in
various cells [21,22,23]. The change of AQP5 expression in breast
cancer cells was examined in response to extracellular hyperos-
motic stress induced by sorbitol-containing medium. MCF7 cells
were incubated with either 100 mM or 200 mM sorbitol for 24 h,
Figure 1. Expression of AQP5 mRNA and protein in human breast cancer cells. A) Products of the predicted sizes were generated by RT-
PCR of AQP5 (189-bp) and GAPDH (287-bp) in human breast cancer cells (MCF7 and MDA-MB-231), and human lung cancer cells (A549). Negative
controls included the omission of reverse transcriptase (- RT). -; Reverse Transcriptase (RT)-negative; +; Reverse Transcriptase (RT)-positive. B)
Expression of AQP5 protein was investigated in total cell lysate of breast cancer cells. Immunoblotting analysis of AQP5 (32 kDa) and b-actin (43 kDa)
was performed in lysates of ERa-positive MCF7 and ERa-negative MDA-MB-231 cells.
doi:10.1371/journal.pone.0028492.g001
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Expression of AQP5 protein was significantly decreased in the cells
exposed to either 100 mM (5769%, P,0.05, Fig. 4A and B) or
200 mM sorbitol medium (5866%, P,0.05, Fig. 4A and B),
compared with the cells maintained under isosmotic condition
(300 mOsm/KgH2O). To examine whether culture medium
containing sorbitol induced non-specific downregulation of
proteins, change of ERa expression was also examined (Fig. 4).
ERa expression in the MCF7 cells was not affected in response to
100 mM sorbitol medium, but decreased in 200 mM sorbitol
medium, indicating that hyperosmotic stress induced by 100 mM
sorbitol for 24 h caused a selective decrease of AQP5 expression in
MCF7 cells. In addition, 17b-estradiol (E2) treatment (10
29 M,
24 h) in MCF7 cells induced a significant decrease of ERa
expression in MCF7 cells, as previously demonstrated [24].
Moreover, RT-PCR analysis revealed that AQP3 and AQP7
mRNAexpression was alsoobserved inhuman breastcancerMCF7
cells, in addition to AQP5 expression (Fig. 4C). Since it was reported
that AQP3 expression in cultured human keratinocytes was
increased under hypertonic condition [21], the changes of protein
expression of AQP3 and AQP5 were studied in MCF7 cells under
hyperosmotic environment (380 mOsm/KgH2O) for 1 day or 3
days induced by 100 mM sorbitol. As shown in Figure 4 (panel D
and E), hyperosmotic stress by sorbitol significantly reduced AQP5
expression in time-dependent manner, whereas AQP3 expression
was unchanged, revealing that sorbitol-induced hyperosmotic stress
induced a selective decrease of AQP5 expression in MCF7 cells.
Inhibition of proliferation and migration of MCF7 cells in
response to sorbitol-induced hyperosmotic stress
To test the effects of sorbitol-induced hyperosmotic stress and
hence the selective decrease of AQP5 expression on the cell
proliferation, MCF7 cells were incorporated by BrdU for another
24 h in the presence of 100 mM sorbitol after an incubation with
100 mM sorbitol for 24 h. Sorbitol-treated MCF7 cells showed
significantly reduced BrdU incorporation (6063% of control
levels, P,0.05, Fig. 5A). Moreover, migration of MCF7 cells was
also inhibited by 100 mM sorbitol treatment (3163% of control
levels, P,0.05, Fig. 5B–C). Therefore, hyperosmotic stress by
100 mM sorbitol and hence selective AQP5 downregulation could
decrease the cell proliferation and migration of human breast
cancer cells (ERa-positive MCF7 cells).
Discussion
In this study, we demonstrated that AQP5 is likely to play a role
in proliferation and migration of human breast cancer cells. RT-
PCR and immunoblotting analysis revealed the expression of
AQP5 mRNA and protein in human breast cancer cells and
immunohistochemistry demonstrated AQP5 labeling in the ductal
epithelial cells of human breast tissues. Importantly, prominent
AQP5 labeling was associated with invasive cancer cells combined
with the gradual decrease of AQP5 labeling intensity in the ductal
epithelial cells during the progression of breast carcinoma.
Moreover, AQP5 polarity in the apical plasma membrane domain
of the ductal epithelial cells was lost. Semi-quantitative assessment
of AQP5 labeling intensity in the invasive cancer cells demon-
strated that AQP5 labeling intensity was significantly higher in the
invasive carcinoma with LN metastasis, compared with the one
without LN metastasis, despite no differences in tumor grade
between the two groups. Cell culture experiments also revealed the
role of AQP5 in tumor cell proliferation and migration. Lentivirus-
mediated AQP5-shRNA transduction or sorbitol-induced hyper-
osmotic stress in human breast cancer cells resulted in the
Figure 2. Immunohistochemistry of AQP5. Immunoperoxidase labeling of AQP5 on the sections of tissues from benign breast tumor (A–C), and
invasive ductal carcinoma of breast in human patients (D–I; lymph node-negative (D–F) and lymph node-positive (G–I). DT, duct.
doi:10.1371/journal.pone.0028492.g002
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with markedly decreased cell proliferation and migration.
Recent studies suggest that AQP is regarded as an important
oncogenic factor for tumor progression [5,6,7,10]. It has been
reported that AQP5 is expressed in the ductal epithelial cells of
various secretory tissues, such as lung and salivary glands
[15,25,26]. In the present study, AQP5 mRNA and protein are
expressed in human breast cancer cell lines, MCF7 and MDA-
MB-231, both of which are originated from breast ductal epithelial
cells. Moreover, immunohistochemistry revealed the localization
of AQP5 at the ductal epithelial cells of human breast cancer
tissues. Since tumorigenesis occurs in ductal epithelial cells, and
some begin in lobular cells of breast [27,28], the observed
localization of AQP5 suggests that it may play an important role in
tumorigenesis and progression of ductal carcinoma of breast.
Importantly, we demonstrated that intense AQP5 labeling was
seen in the invasive ductal carcinoma cells in human patients
exhibiting LN metastasis. This finding is compatible with several
previous studies revealing that AQP5-overexpressing cancer cells
exhibit increased ability of cell proliferation and migration, e.g.,
chronic myelogenous leukemia [16], colorectal carcinoma [14],
and non small cell lung carcinoma (NSCLC) [15]. Thus, increased
AQP5 expression in the invasive ductal carcinoma of breast could
suggest its role in the promotion and cell growth of cancer cells.
Consistent with this, previous studies demonstrated that AQP5-
overexpressing cancer cells exhibit the increased ability of cell
proliferation and migration via several different signaling path-
ways. Zhang, et al. [29] demonstrated that epidermal growth factor
receptor, extracellular receptor kinases, and p38 mitogen-activated
protein kinase pathways were activated in lung cancer cell line
SPC-A1 and PC-9 stably transfected with AQP5, resulting in the
promotion of cell proliferation and migration. They also showed
significantly increased PCNA and c-myc expression in AQP5
transfected cells (28). In addition, MUC5AC mucin expression was
increased, which might be involved in lung cancer metastasis (28).
AQP5-overexpressed NIH3T3 cells also exhibited cell prolifera-
tion via Ras signal transduction (4), and invasive and metastatic
phenotype in various tumors was associated with AQP5 binding to
SH3 domains of c-Src, a non-receptor cytoplasmic tyrosine kinase
(15).
In contrast, shRNA-mediated AQP5 knockdown in SPC-A1
cells was associated with decreased cell migration and invasion,
presumably by changing cell shape and volume through the
decreased osmotic water permeability of cell membrane [30]. In
the present study, we also demonstrated significantly decreased cell
proliferation and migration of human breast cancer cells with
shRNA- or hyperosmotic stress-mediated AQP5 knockdown.
Osmolar changes have been revealed to affect to cell proliferation,
as previously demonstrated by the negative effect of hypertonicity
on cell proliferation[31]. Kato, et al. [32] also demonstrated that
alkaline phosphatase activity was increased in MCF7 cells by
hyperosmolar stress, and the increased alkaline phosphatase
activity was known to be associated with reduction of cell
proliferation [33,34]. In the present study, sorbitol treatment
suppressed the migration and proliferation of breast cancer cells,
where AQP5 expression was significantly decreased, but not
Table 1. Tumor grade and semi-quantitative measurement of AQP5 labeling intensity and proportion in the invasive ductal
carcinoma with or without lymph node metastasis.
Type Patients Tumor grade*
Tubule formation /Nuclear
grade /Mitotic rate
AQP5 labeling
intensity
Proportion of
AQP5 labeling
Lymph node- 1 3 3/3/3 - -
negative invasive 2 2 3/2/2 - -
Carcinoma 3 3 3/2/3 2 3
4 2 3/2/1 - -
5 1 3/1/1 3 3
6 3 3/3/3 2 2
7 1 2/2/1 - -
8 2 3/2/1 - -
9 2 3/2/2 N.A. N.A.
10 2 3/2/1 N.A. N.A.
Lymph node- 1 2 3/2/2 1 2
positive invasive 2 3 3/3/2 2 2
Carcinoma 3 2 3/2/1 2 3
4 3 3/3/3 2 2
5 2 3/2/1 3 3
6 2 3/2/2 3 3
7 1 1/2/1 1 1
8 2 3/2/2 3 3
9 2 3/3/1 3 3
10 2 3/2/2 3 3
Tumor grade was determined by modified Bloom-Richardson-Elston grading system. Immunolabeling intensity of AQP5 was scored as negative (-), weak (score 1),
moderate (score 2), and strong (score 3) by expert pathologists. Proportion was the approximate numbers of AQP5-positive tumor cells among the total tumor cells,
scored as negative(-), ,33% (score 1), 34%–66% (score 2), and.67% (score 3). N.A., not available.
doi:10.1371/journal.pone.0028492.t001
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particularly osmolar condition, could be importantly involved in
the proliferation and migration of breast cancer cells. Further
studies are required to elucidate the specific underlying molecular
mechanisms for 1) increased AQP5 expression with loss of
subcellular polarity of expression in the invasive carcinoma; and
2) the direct association between up-regulated AQP5 expression
and progression of cancer cells.
In summary, prominent AQP5 expression was seen in the cancer
cells with the loss of polarity of ductal epithelia during the
progression of invasive ductal carcinoma of breast. More prominent
AQP5 labeling intensity of the cancer cells was seen in the invasive
carcinoma with LN metastasis than that of the invasive carcinoma
without LN metastasis, whereas there was no difference in the
tumor grade between the two groups. shRNA- or hyperosmotic
stress-induced reduction of AQP5 expression was associated with
significantly reduced cell proliferation and migration, demonstrated
by in vitro cell culture experiments of MCF7 cells. Therefore, AQP5
expression could be a novel biomarker for cell growth and
metastasis of human breast cancer, and hence AQP5 might be a
critical target for anti-breast cancer treatment.
Materials and Methods
Cell line and Tissue specimen from human patients
Breast cancer cell lines MCF7 (HTB-22) and MDA-MB-231
(HTB-26) were obtained from the American Type Culture
Collection (Manassas, VA), and cells were cultured in DMEM
medium containing 0.1% penicillin-streptomycin solution and
10% heat-inactivated FBS at 37uC.
ImmunohistochemicalexaminationofAQP5onthetissuesections
were performed using paraformaldehyde-immersion fixed and
paraffin-embedded tissues of benign breast tumor and invasive
ductalcarcinoma(Table2),obtainedfromDepartmentofPathology,
Kyungpook National University Hospital. The breast tumor samples
were obtained from 2000 to 2010. Theses tissues included 10 benign
tumors and 20 invasive ductal carcinoma (10 non-LN metastases
and 10 LN metastases, Table 2). Tumor grade was determined by
modified Bloom-Richardson-Elston grading system.
Ethics statement
Paraformaldehyde-immersion fixed and paraffin-embedded
tissues of breast tumor were obtained from Department of
Figure 3. Changes in proliferation and migration of MCF7 cells infected by lentivirus containing human AQP5 shRNA. A and B) Semi-
quatitative immunoblotting of AQP5. AQP5 expression was significantly decreased in the AQP5 shRNA-infected MCF7 cells, compared to the mock
shRNA-infected MCF7 cells. n, number of MCF7 cell lysates. C) BrdU cell proliferation assay. AQP5 shRNA- or mock shRNA-infected MCF7 cells were
incorporated with BrdU for 24 h, and ELISA demonstrated a significant decrease of BrdU incorporation in the MCF7 cells with AQP5 knockdown. D)
Cell migration assay for MCF7 cells with AQP5 knockdown. MCF7 cells with AQP5 knockdown were incubated in upper chamber of 24-transwell plate
for 4 h, and migration was induced by FBS-gradient medium. Migrated cells were stained by crystal violet solution and counted in five different fields
(6100) per well. Value of migrated cells was described as the total cell number in five random fields, and two-independent experiment was
performed. *P,0.05 when compared to mock shRNA-infected control group.
doi:10.1371/journal.pone.0028492.g003
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Semiquantitative immunoblotting of AQP5 and ERa in MCF7 cells treated by vehicle, E2 (10
29 M), and sorbitol (100 mM or 200 mM) for 24 h. n,
number of MCF7 cell lysates. C) RT-PCR of AQP3, -5, -7, -9, and GAPDH in human breast cancer cell line, MCF7. The primer sequences are described in
Table S2. Negative controls included the omission of reverse transcriptase (- RT). -; Reverse Transcriptase (RT)-negative; +; Reverse Transcriptase (RT)-
positive. D and E) Semiquantitative immunoblotting of AQP3 and AQP5 in MCF7 cells treated by 100 mM sorbitol for 1 d or 3 d. *P,0.05 when
compared to vehicle-treated control group (AQP5), and
#P,0.05 when compare to vehicle-treated control group (ERa).
doi:10.1371/journal.pone.0028492.g004
Figure 5. Change of proliferation and migration of sorbitol-treated MCF7 cells. A) BrdU cell proliferation assay. MCF7 cells incubated in
100 mM sorbitol medium for 24 h were incorporated with BrdU for another 24 h. B and C) Cell migration assay for sorbitol-treated MCF7 cells.
*P,0.05 when compared to vehicle-treated control group.
doi:10.1371/journal.pone.0028492.g005
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approval of the Institutional Review Board (IRB No. 2011-04-
015). The H&E stained slides were re-evaluated anonymously by
pathologists. Informed consent from all patients involved in this
study was not obtained, since the data were evaluated anony-
mously. The ethics committee of IRB, Kyungpook National
University Hospital, specifically waived the need for consent.
RT-PCR analysis of AQP5
Total RNA from human breast cancer cell lines was extracted
using TRI reagent (Molecular Research Center, Cincinnati, OH).
Total RNA was used and one-step RT-PCR was performed using
Access RT-PCR system (Promega, Medison, WI) according to the
manufacturer’s instructions [35]. For RT-PCR, the following
components were added to the reaction vials: 780 ng of total
RNA, both sense and antisense primers, AMV/Tfl 56reaction
buffer, dNTP mix, 25 mM MgSO4, AMV reverse transcriptase,
Tfl DNA polymerase, and DEPC-treated water in a total volume
of 50 ml. The samples were incubated for 45 min at 45uC,
thereafter RT was terminated by heating at 94uC for 2 min. And
then, the samples were subjected to thermal cycling for the second
strand cDNA synthesis and amplification. Amplification was
performed for 40 cycles with 30 s/94uC denaturation, 1 min/
60uC annealing, and 2 min/68uC extension. An amplification of
the mRNA for housekeeping gene hGAPDH was used as an
internal control. The primer sequences were as follows: hAQP5
sense; 59- CAGCTGGCACTCTGCATCTT-39, antisense; 59-
TGAACCGATTCATGACCACC-39, hGAPDH sense; 59-
GCCAAAAGGGTCATCATCTC-39, antisense; 59-GTAGAGG-
CAGGGATGATGTTC-39. RT-PCR products were electropho-
resed on 1.5% agarose gel containing ethidium bromide.
AQP5 knockdown using lentivirus containing AQP5 short
hairpin RNA
Short hairpin RNA (shRNA) set (RHS4533-NM_001651) for
human AQP5 (accession: NM_001651) were purchased from
Open biosystems (Huntsville, AL). The sequences for AQP5
shRNA are listed in Table S1. Lentivirus containing AQP5
shRNA was prepared using the lentiviral packaging system
(ViraPower Lentiviral Expression System, Invitrogen), as described
previously [36]. Viral DNA and AQP5 shRNA-containing
pLKO.1 vector were transfected into 293FT cells and incubated
for 4 days. Then, the supernatant of 293FT cell cultures
containing viral particles (1/5 volume of fresh breast cancer cell
culture medium) was added to breast cancer cells cultured in 3
different well plates (n=3 in Fig 3A) with 16 ng/mL polybrene.
After incubation for 2 days, cells were screened in the medium
containing puromycin (2 mg/mL) for 2 weeks.
During this screening procedure, the proliferation of MDA-
MB-231 cells were markedly retarded compared to MCF7 cells
and hence MDA-MB-231 cells were not collected for doing
further experiments. After selection of MCF7 cells, protein
expression of AQP5 was analyzed by immunoblotting. Lentiviral
pLKO.1 vector transduced-cells were the negative control
(Mock). The number of replicates in the figures (Fig. 3, 4, 5)
indicates the number of cell lysate preparations from independent
experiments.
Immunoblotting analysis
The cell lysates were obtained in RIPA buffer (10 mM Tris-
HCl, 0.15 M NaCl, 1% NP-40, 1% Na-deoxycholate, 0.5% SDS,
0.02% sodium azide, 1 mM EDTA, pH 7.4) including proteinase
and phosphatase inhibitors (0.4 mg/ml leupeptin, 0.1 mg/ml
pefabloc, 1 mM Na3VO4, 25 mM NaF, and 0.1 mM okadaic
acid). Immunoblotting was performed as previously described
[37]. The total protein concentration was measured (Pierce BCA
protein assay reagent kit; Pierce, Rockford, IL) and all samples
were adjusted with RIPA buffer to reach the identical final protein
concentrations and solubilized at 65uC for 15 minutes in Laemmli
sample buffer, and then stored at 4uC. Primary antibodies used
were anti-AQP5 (1:1,000, Abcam), anti-estrogen receptor a
(1:1,000, Cell Signaling) and anti-b-actin (1:100,000, Sigma).
The film was scanned (EPSON Perfection V700 Scanner, Long
Beach, CA) and band density was quantitated by Image J (NIH
Image, NIMH, NIH, Bethesda, MD). The densitometry values for
each protein were corrected by densitometry of b-actin and were
normalized to facilitate comparisons.
Immunohistochemistry
Paraffin-embedded blocks of 4% paraformaldehyde (PFA)-fixed
human breast tumor tissues (IRB No. 2011-04-015, Kyungpook
National University Hospital) were prepared for 2 mm thickness
sections on the slides. The sections were labeled by anti-AQP5
antibody (1:200, Abcam) at 4uC overnight, then by a horseradish
peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody
(1:200, P448; DAKO) for 90 min at room temperature, as
previously described [26]. AQP5 immunolabeling was reviewed
Table 2. Clinical characteristics of breast cancer patients from three different groups.
Category Benign tumor
Lymph node negative
Invasive ductal carcinoma
Lymph node positive
Invasive ductal carcinoma
Age 18–55 (mean: 43.6) 36–66 (mean: 50.3) 39–64 (mean: 47.7)
Tumor size (cm) - .10 mm but#20 mm in greatest
dimension (T1c) (n=5)
.20 mm but#50 mm in greatest
dimension (T2) (n=5)
.10 mm but#20 mm in greatest
dimension (T1c) (n=2)
.20 mm but#50 mm in greatest
dimension (T2) (n=8)
Stage - IA (n=5)
IIA (n=5)
IIA (n=1)
IIB (n=7)
IIIC (n=2)
Diagnosis Fibrocystic change (n=6)
Fibroadenoma (n=2)
Intraductal papilloma (n=1)
Gynecomastia (n=1)
Invasive ductal carcinoma (n=9)
Invasive pleomorphic lobular
carcinoma (n=1)
Invasive ductal carcinoma (n=10)
n, number of patients in each group.
doi:10.1371/journal.pone.0028492.t002
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scored. Immunolabeling intensity of AQP5 was scored as negative
(-), weak (score 1), moderate (score 2), and strong (score 3).
Proportion is the approximate numbers of AQP5-positive tumor
cells among the total tumor cells, scored as negative (-),,33%
(score 1), 34%–66% (score 2), and .67% (score 3).
BrdU cell proliferation assay
BrdU cell proliferation assay was carried out according to the
manufacturer’s instructions (QIA58, Calbiochem). Briefly breast
cancer cells (1610
4 MCF7 cells/well), either lentiviral pLKO.1
vector transduced-cells (Mock, n=10 in Fig 3C) or lentivirus
containing AQP5 shRNA-infected cells (AQP5 shRNA, n=10 in
Fig 3C), were allowed to attach to the culture plate at 37uC
overnight. For BrdU incorporation, culture media was changed to
fresh culture media containing BrdU (1:2,000) and incubated for
24 h at 37uC. After washing, fixative/denaturing solution was
added to each well and kept for 30 min at room temperature. The
cells were then treated by anti-BrdU antibody (1:100) for 1 h at
room temperature. For conjugation of peroxidase goat anti-mouse
IgG to anti-BrdU antibody, 100 mL of secondary antibody
conjugate solution was added into each well. Free conjugates
were removed by washing with wash buffer three times and
distilled water. Then, after removal of contents of wells, substrate
solution was added to each well and incubated for 15 min in the
dark at room temperature. The reaction between HRP and
substrates was stopped by addition of stop solution. Absorbance of
each well was measured using a spectrophotometric plate reader at
wavelength of 520 nm. BrdU incorporation was calculated by the
following equation: BrdU incorporation=[(absorbance of treated
well) - (absorbance of non-BrdU labeled well)]/[(absorbance of
control well) - (absorbance of non-BrdU labeled well)].
Cell migration assay
MCF7 cells were studied in a permeable filter of transwell
system (8 mm pore size, TranswellH Permeable Supports, Cat.
No. 3422, Corning Incorporated, MA). For coating the mem-
brane of inserts, the side of membrane facing lower chamber of the
inserts was coated with 10 ng/mL collagen IV solution (C5533,
Sigma) at 4uC overnight, and blocked by 2% BSA/PBS solution
for 1 h at room temperature. After trypsinization, cell suspension
(1610
4 cells/well) was seeded into the membrane facing upper
chamber containing culture medium with 1% FBS. Cell migration
to the other side of membrane was induced by 10% FBS-
containing medium in the lower chamber for 4 h. Migrated cells
were fixed in 4% PFA solution for 10 min and then stained in
0.03% crystal violet solution for 10 min. After removal of un-
migrated cells by swab, the stained cells were subjected to
microscopic examination. Migrated cells were counted in the five
randomly selected fields (6100) per well, respectively.
Statistical analysis
Values were presented as means 6 standard errors. Statistical
comparisons were accomplished by unpaired t test (when the
number of groups were 2) or by one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparisons test
(when the number of groups was more than 2). Multiple
comparisons tests were only applied when a significant difference
was determined in the ANOVA, P,0.05.
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